Should I buy or sell Sigilon Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares. View SGTX analyst ratings or view top-rated stocks .

What is Sigilon Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%. View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts .

How were Sigilon Therapeutics' earnings last quarter?

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced its earnings results on Wednesday, November, 10th. The company reported ($8.19) earnings per share for the quarter, beating the consensus estimate of ($8.58) by $0.39. The business earned $1.95 million during the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%.

When did Sigilon Therapeutics' stock split?

Sigilon Therapeutics shares reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did Sigilon Therapeutics IPO?

Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.

NASDAQ:SGTX

Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free SGTX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $22.09
▼
$23.10
50-Day Range: $20.92
▼
$23.06
52-Week Range: $3.77
▼
$28.00

Volume: 83,600 shs
Average Volume: 62,902 shs
Market Capitalization: $56.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Stock Analysis

Get Sigilon Therapeutics alerts:

Sigilon Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 6.5% Downside
$21.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($12.65) to ($13.01) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.00 out of 5 stars

Medical Sector

914th out of 914 stocks

Pharmaceutical Preparations Industry

424th out of 424 stocks

1.0

Analyst's Opinion

Consensus Rating
Sigilon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sigilon Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SGTX.

0.0

Dividend Strength

Dividend Yield
Sigilon Therapeutics does not currently pay a dividend.
Dividend Growth
Sigilon Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGTX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Sigilon Therapeutics this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sigilon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Sigilon Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Sigilon Therapeutics are expected to decrease in the coming year, from ($12.65) to ($13.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sigilon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sigilon Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sigilon Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Sigilon Therapeutics Stock (NASDAQ:SGTX)

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SGTX Stock News Headlines

April 14, 2024 | seekingalpha.com

MCRB Seres Therapeutics, Inc.

October 22, 2023 | wsj.com

Beam Therapeutics Inc.

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

August 14, 2023 | markets.businessinsider.com

Eli Lilly Concludes Acquisition Of Sigilon Therapeutics

August 14, 2023 | finance.yahoo.com

Lilly Completes Acquisition of Sigilon Therapeutics

August 1, 2023 | finance.yahoo.com

SGTX - Sigilon Therapeutics, Inc.

July 31, 2023 | msn.com

Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked

July 21, 2023 | businesswire.com

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

July 18, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNM

July 6, 2023 | msn.com

Canaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy Recommendation

July 6, 2023 | msn.com

Sigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28

July 3, 2023 | msn.com

5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for Pismo

June 29, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. Buyout

June 29, 2023 | finance.yahoo.com

Moderna Billionaire Set to Score 3,000% Gain on Tiny Biotech

June 29, 2023 | finanznachrichten.de

Eli Lilly and Company: Lilly to Acquire Sigilon Therapeutics

June 29, 2023 | msn.com

Health Care Company Eli Lilly Announces Acquisition of Sigilon Therapeutics

June 29, 2023 | bizjournals.com

Sigilon stock up 500% on Lilly acquisition news

June 29, 2023 | finance.yahoo.com

Sigilon Therapeutics Shares Are Shooting Higher Today - What's Going On

June 29, 2023 | msn.com

Sigilon stock skyrockets 650% on buyout deal with Eli Lilly

June 29, 2023 | markets.businessinsider.com

Eli Lilly To Acquire Sigilon Therapeutics

June 29, 2023 | msn.com

Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?

June 29, 2023 | technews.tmcnet.com

SGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to Shareholders

June 29, 2023 | finance.yahoo.com

Lilly to Acquire Sigilon Therapeutics

June 29, 2023 | finance.yahoo.com

Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments

May 26, 2023 | markets.businessinsider.com

Morgan Stanley Sticks to Their Hold Rating for Sigilon Therapeutics (SGTX)

May 25, 2023 | msn.com

Morgan Stanley Maintains Sigilon Therapeutics (SGTX) Equal-Weight Recommendation

See More Headlines

Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SGTX
CUSIP: N/A
CIK: 1821323
Web: sigilon.com
Phone: 617-336-7540
Fax: N/A
Employees: 62
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $21.00
Low Stock Price Target: $21.00
Potential Upside/Downside: -6.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($12.2328)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,560,000.00
Net Margins: -171.29%
Pretax Margin: -171.29%
Return on Equity: -83.07%
Return on Assets: -38.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.78
Quick Ratio: 1.78

Sales & Book Value

Annual Sales: $12.94 million
Price / Sales: 4.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.68 per share
Price / Book: 1.43

Miscellaneous

Outstanding Shares: 2,510,000
Free Float: 2,351,000
Market Cap: $56.40 million
Optionable: Not Optionable
Beta: 4.12

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Rogerio Vivaldi Coelho M.B.A. (Age 59)
M.D., MBA, Pres, CEO & Director
Comp: $924.67k
Mr. Philip Ashton-Rickardt Ph.D. (Age 59)
Chief Scientific Officer
Comp: $614.08k
Dr. Robert S. Langer Jr. (Age 74)
Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
Dr. Daniel G. Anderson Ph.D. (Age 53)
Co-Founder & Member of Scientific Advisory Board
Dr. Omid Veiseh Ph.D.
Co-Founder
Dr. José Oberholzer M.D.
Co-Founder
Dr. Arturo Vegas Ph.D.
Co-Founder
Mr. Josias Fantato De Pontes M.B.A. (Age 56)
CFO, Principal Accounting Officer & Treasurer
Mr. Bernd Kullmann M.B.A.
Sr. VP and Head of Operations & Project Management
Mr. Matthew P. Kowalsky J.D. (Age 50)
Chief of Staff, Chief Legal and Admin. Officer & Sec.

Key Competitors

View All Competitors

Insiders

Lilly & Co Eli
Bought 1,718,493 shares on 8/11/2023
Total: $25.64 M ($14.92/share)

SGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Sigilon Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View SGTX analyst ratings or view top-rated stocks.
What is Sigilon Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued 1 year target prices for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%.
View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts.
How were Sigilon Therapeutics' earnings last quarter?: Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced its earnings results on Wednesday, November, 10th. The company reported ($8.19) earnings per share for the quarter, beating the consensus estimate of ($8.58) by $0.39. The business earned $1.95 million during the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%.

When did Sigilon Therapeutics' stock split?: Sigilon Therapeutics shares reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
When did Sigilon Therapeutics IPO?: Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.

This page (NASDAQ:SGTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

Sigilon Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Sigilon Therapeutics Stock (NASDAQ:SGTX)

SGTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

SGTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™